1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 24,840 | -0,52 % | Ionis Aktie: Alles auf den Punkt gebracht | Ionis Pharmaceuticals verstärkt Zusammenarbeit mit Sobi und fördert weltweite Olezarsen-Vermarktung außerhalb der USA. Ionis Pharmaceuticals stärkt seine Position im Biotechnologiesektor durch strategische... ► Artikel lesen | |
| CSPC PHARMA | 0,602 | -2,21 % | Aktienmarkt: CSPC Pharmaceutical Group-Aktie kann sich nicht behaupten (0,6116 €) | Im Wertpapierhandel notiert das Wertpapier der CSPC Pharmaceutical Group derzeit leichter. Das Papier kostete zuletzt 0,61 Euro. Jahreschart der CSPC Pharmaceutical Group Ltd-Aktie, Stand 17.04.2025... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 12,810 | -1,23 % | ACADIA PHARMACEUTICALS INC - 8-K, Current Report | ||
| SELLAS LIFE SCIENCES | 1,180 | +3,51 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML | - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 264,10 | -1,42 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer | CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,805 | -0,10 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals | CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,063 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 0,651 | -1,36 % | Craig-Hallum sets $6 target for Opus Genetics stock, rates it a Buy | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| VIRACTA THERAPEUTICS | 0,008 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 10.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.02.2025ISIN NameES0105015012 LAR... ► Artikel lesen | |
| SAVARA | 2,620 | +3,15 % | Savara Inc.: Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences | Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 1,180 | +1,72 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,400 | -2,10 % | Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2024 | April 11, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals... ► Artikel lesen | |
| PHOTOCURE | 4,415 | +0,68 % | Photocure ASA - Notice of the Annual General Meeting 5 May 2025 | ||
| CGN MINING | 0,146 | 0,00 % | CGN MINING (01164): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION |
NATTOPHARMA ASA gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.
